SomaLogic Announces Strategic Collaboration with University Hospitals Cleveland Medical Center to Treat Diabetic Patients at High Risk of Cardiovascular Disease
SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with one of the nation’s leading academic medical centers, University Hospitals Cleveland Medical Center, where they will evaluate the impact of the company’s SomaSignal™ tests on the medical management of diabetic patients who are at a higher risk of cardiovascular disease.
As part of the collaboration, University Hospitals (UH) Cleveland Medical Center and SomaLogic will promote the use of proteomic data to identify diabetic patients who are at higher risk for cardiovascular disease and track the effectiveness of treatments used for these patients. The collaboration will include clinical trials and development projects that establish the groundwork for the use of proteomics in the health care system as part of their larger vision for building healthier communities, improving patient care and reducing healthcare costs.
“We share a common vision with University Hospitals for finding innovative patient solutions for cardiovascular diseases,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “We’re excited to see our high-plex proteomic SomaSignal tests used to support physicians in their efforts to improve their patients’ health outcomes.”
The collaboration with UH Cleveland Medical Center is part of SomaLogic’s SomaSignal™ Proteomics for Precision Medicine Initiative, the first large-scale, clinically focused partnership effort aimed at equipping healthcare providers with the power of proteomic technology to inform decisions at the point of care. SomaLogic can run approximately 7,000 protein measurements on a single 55-microliter plasma or serum sample. The company has run approximately 520,000 samples as of September 2021.
Sanjay Rajagopalan, M.D., Chief of the Division of Cardiovascular Medicine, Chief Academic and Scientific Officer for the UH Harrington Heart & Vascular Institute and Herman Hellerstein Professor of Cardiovascular Medicine, said, “This partnership with SomaLogic consolidates the vision of UH and UH Harrington Heart & Vascular Institute to be a leader in precision medicine platforms to guide decision making. Given the breadth of expertise in precision medicine tools at UH, particularly in the imaging space, that are readily available to clinicians, we were a natural choice to extend these approaches to emerging next-generation proteomic methods. SomaLogic was the logical partner given their expertise and incredibly exciting data that allows one to identify patients at risk going beyond relatively dated and modestly effective clinical risk score algorithms.”
The Principal Investigators for this proposal are Sadeer Al-Kindi, M.D. and Ian Neeland, M.D., Co-Directors of CINEMA, UH’s nationally recognized cardiometabolic program. The project will directly involve identification of at-risk Type 2 diabetes patients who may be candidates for evidence based therapies such as SGLT-2 inhibitors and GLP-1 agonists.